Last quarter (Q ), NLS Pharmaceutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, NLS Pharmaceutics's net income was $―. See NLS Pharmaceutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	$ 16.30M	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	$ 16.30M	-	-	-	-
Operating Expense	-	$ -15.48M	$ 11.86M	$ 2.30M	$ 4.20M	$ 3.45M
Operating Income	-	$ -15.48M	$ -11.86M	$ -2.30M	$ -4.20M	$ -3.45M
Net Non Operating Interest Income Expense	-	$ -100.87K	$ -68.13K	$ -233.70K	$ -819.71K	$ -1.08M
Other Income Expense	-	$ -110.99K	$ 17.32K	$ -328.37K	$ -430.39K	$ -613.20K
Pretax Income	-	$ -15.47M	$ -12.08M	$ -2.86M	$ -5.45M	$ -5.15M
Tax Provision	-	$ -1.00M	$ -1.12M	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	$ -16.39M	$ -12.08M	$ -2.86M	$ -5.45M	$ -5.15M
Basic EPS	-	$ -0.84	$ -1.00	$ -0.27	$ -0.46	$ -0.49
Diluted EPS	-	$ -0.84	$ -1.00	$ -0.27	$ -0.46	$ -0.49
Basic Average Shares	-	$ 19.68M	$ 11.90M	$ 11.78M	$ 11.78M	$ 10.60M
Diluted Average Shares	-	$ 19.68M	$ 11.90M	$ 11.78M	$ 11.78M	$ 10.60M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	$ -15.48M	$ 11.86M	$ 2.30M	$ 4.20M	$ 3.45M
Net Income From Continuing And Discontinued Operation	-	$ -16.50M	$ -12.08M	$ -2.86M	$ -5.45M	$ -5.15M
Normalized Income	-	-	-	$ -2.86M	$ -5.08M	$ -5.15M
Interest Expense	-	-	-	$ 233.70K	$ 819.71K	$ 1.08M
EBIT	-	$ -15.37M	$ -12.01M	$ -2.63M	$ -4.63M	$ -4.06M
EBITDA	-	$ -15.30M	$ -11.96M	$ -2.63M	$ -4.63M	$ -4.06M

Currency in USD

NLS Pharmaceutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing